Key Highlights
- Cash, cash equivalents and investments were approximately USD 1.05 billion.
- Research and development expenses were USD 46.1 million.
- DT120 has received two FDA breakthrough therapy designations.
- Voyage enrolled 214 participants; Panorama enrolled 245.
Definium Therapeutics, Inc. (NASDAQ:DFTX) reported third quarter 2026 results, with cash, cash equivalents and investments of approximately USD 1.05 billion as of September 30, 2026, compared with USD 412 million as of December 31, 2025. Reported EPS was negative USD 0.46, compared with an estimate of negative USD 0.56. The company reported no revenue.
Research and development expenses were USD 46.1 million for the third quarter of 2026, compared with USD 31 million for the same period in 2025.
Phase III Results for DT120
Management described positive Phase III results across three studies and two large psychiatric indications. In each study, a single 100 microgram dose produced rapid and durable improvements.
Voyage enrolled 214 participants with moderate to severe generalized anxiety disorder and met its primary endpoint and all key secondary efficacy endpoints. At week 12, DT120 showed a 5.4 point placebo adjusted improvement on the Hamilton Anxiety Rating Scale with a p value of less than 0.0001 and a Cohen's d of 0.81. Improvement was evident as soon as the first assessment at week 1 and was maintained through week 12.
Panorama enrolled 245 participants. The 100 microgram dose led to a 5.1 point placebo adjusted improvement on the HAM-A at week 12 with a p value of less than 0.0001 and a Cohen's d of 0.64. Management said the 50 microgram functional control supported the interpretability of the efficacy and the selection of the 100 microgram dose.
Management said the EMERGE results in major depressive disorder, announced in June, met the primary endpoint and all key secondary endpoints.
Regulatory Progress
DT120 has received two FDA breakthrough therapy designations. Management said its engagement with the FDA remains constructive and cited a planned NDA filing in the first half of 2027. It also said it is focused on readiness to deliver the treatment to patients and health care providers if approved, and that realizing the full potential of DT120 requires more than clinical data.
Pipeline Update
The company shared initial results from its DT402 study in adults with autism spectrum disorder, which management said showed encouraging signals across measures of socialization, communication and functional outcomes. The company's webcast referenced its filings with the SEC and applicable Canadian securities regulators, including the Annual Report on Form 10-K and the Form 10-Q filed the same day. Management said it is advancing with urgency toward the planned filing. Management cited these findings as support for continued Investment in DT402 and for its goal of building a company with multiple products across therapeutic areas.
The change in cash and investments from USD 412 million at year end to approximately USD 1.05 billion at September 30, 2026 is the main Balance Sheet figure disclosed on the call. The increase in Research and Development expenses from USD 31 million to USD 46.1 million is the main Operating Expense figure disclosed.
Three Phase III Studies and Filing Timeline
Definium's DT120 program reported results from three Phase III studies, including Voyage with 214 participants and Panorama with 245, together with p values and Cohen's d figures. The drug has received two FDA breakthrough therapy designations, and the company cited the filing timeline alongside USD 1.05 billion in cash, equivalents and investments and R&D expense of USD 46.1 million.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...